California Public Employees Retirement System Decreases Stock Holdings in Edwards Lifesciences Corporation $EW

California Public Employees Retirement System lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 976,943 shares of the medical research company’s stock after selling 26,580 shares during the quarter. California Public Employees Retirement System owned about 0.17% of Edwards Lifesciences worth $78,234,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EW. Norges Bank purchased a new stake in Edwards Lifesciences in the fourth quarter valued at about $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares during the last quarter. Viking Global Investors LP purchased a new stake in shares of Edwards Lifesciences during the third quarter worth about $238,688,000. Marshall Wace LLP increased its holdings in shares of Edwards Lifesciences by 66.1% during the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock valued at $505,160,000 after acquiring an additional 2,359,128 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Edwards Lifesciences by 221.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,060,891 shares of the medical research company’s stock valued at $167,468,000 after acquiring an additional 1,419,022 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on EW. Barclays reiterated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Truist Financial upped their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research note on Thursday. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a report on Wednesday, April 1st. TD Cowen reaffirmed a “buy” rating and issued a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Finally, Mizuho lifted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $98.95.

Edwards Lifesciences Trading Down 0.0%

Shares of NYSE:EW opened at $85.72 on Monday. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The stock has a market cap of $49.36 billion, a price-to-earnings ratio of 45.60, a PEG ratio of 2.15 and a beta of 0.86. The business has a 50-day moving average price of $87.34 and a 200-day moving average price of $83.92.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the prior year, the firm earned $0.64 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity

In related news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,577 shares of company stock valued at $3,855,527 in the last ninety days. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.